Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group.
BACKGROUND: Endemic Kaposi's sarcoma (KS) is a clinically and epidemiologically distinct human immunodeficiency virus negative form of KS occurring in Africa. Kaposi's sarcoma is now the most frequently reported cancer in some areas of Africa. OBJECTIVE: To determine if a KS-associated her...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1996
|
| _version_ | 1826306255067545600 |
|---|---|
| author | Chang, Y Ziegler, J Wabinga, H Katangole-Mbidde, E Boshoff, C Schulz, T Whitby, D Maddalena, D Jaffe, H Weiss, R Moore, P |
| author_facet | Chang, Y Ziegler, J Wabinga, H Katangole-Mbidde, E Boshoff, C Schulz, T Whitby, D Maddalena, D Jaffe, H Weiss, R Moore, P |
| author_sort | Chang, Y |
| collection | OXFORD |
| description | BACKGROUND: Endemic Kaposi's sarcoma (KS) is a clinically and epidemiologically distinct human immunodeficiency virus negative form of KS occurring in Africa. Kaposi's sarcoma is now the most frequently reported cancer in some areas of Africa. OBJECTIVE: To determine if a KS-associated herpesvirus (KSHV) is present in both endemic HIV-seronegative and HIV-seropositive KS lesions from African patients. METHODS: Paraffin-embedded tissue specimens from Ugandan patients with KS and non-KS tumor control patients attending a university-based oncology clinic were examined in a blinded case-control study. Tissue DNA specimens were examined for detectable KSHV genome by nested polymerase chain reaction performed at two independent laboratories. RESULTS: We identified KSHV in 17 (85%) of 20 KS tissue specimens from HIV-seronegative patients and 22 (92%) of 24 KS tissue specimens from HIV-infected persons. Kaposi's sarcoma lesions from four HIV-infected persons and four HIV-seronegative persons were positive for KSHV. Unlike previous studies in North America and Europe, three (14%) of 22 non-KS cancer control patients' tissue specimens were also positive for KSHV that resulted in an overall odds ratio of 49.2 (95% confidence interval, 9.1 to 335) for detecting KSHV in KS lesions from patients in Uganda. CONCLUSION: As in North America and Europe, KSHV infection is strongly associated with both HIV-seropositive and HIV-seronegative KS in Africa. However, it is likely that infection with this virus is more highly prevalent in Uganda. |
| first_indexed | 2024-03-07T06:45:10Z |
| format | Journal article |
| id | oxford-uuid:fa9fa751-d54a-4302-8db1-89073cd84605 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:45:10Z |
| publishDate | 1996 |
| record_format | dspace |
| spelling | oxford-uuid:fa9fa751-d54a-4302-8db1-89073cd846052022-03-27T13:07:25ZKaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fa9fa751-d54a-4302-8db1-89073cd84605EnglishSymplectic Elements at Oxford1996Chang, YZiegler, JWabinga, HKatangole-Mbidde, EBoshoff, CSchulz, TWhitby, DMaddalena, DJaffe, HWeiss, RMoore, PBACKGROUND: Endemic Kaposi's sarcoma (KS) is a clinically and epidemiologically distinct human immunodeficiency virus negative form of KS occurring in Africa. Kaposi's sarcoma is now the most frequently reported cancer in some areas of Africa. OBJECTIVE: To determine if a KS-associated herpesvirus (KSHV) is present in both endemic HIV-seronegative and HIV-seropositive KS lesions from African patients. METHODS: Paraffin-embedded tissue specimens from Ugandan patients with KS and non-KS tumor control patients attending a university-based oncology clinic were examined in a blinded case-control study. Tissue DNA specimens were examined for detectable KSHV genome by nested polymerase chain reaction performed at two independent laboratories. RESULTS: We identified KSHV in 17 (85%) of 20 KS tissue specimens from HIV-seronegative patients and 22 (92%) of 24 KS tissue specimens from HIV-infected persons. Kaposi's sarcoma lesions from four HIV-infected persons and four HIV-seronegative persons were positive for KSHV. Unlike previous studies in North America and Europe, three (14%) of 22 non-KS cancer control patients' tissue specimens were also positive for KSHV that resulted in an overall odds ratio of 49.2 (95% confidence interval, 9.1 to 335) for detecting KSHV in KS lesions from patients in Uganda. CONCLUSION: As in North America and Europe, KSHV infection is strongly associated with both HIV-seropositive and HIV-seronegative KS in Africa. However, it is likely that infection with this virus is more highly prevalent in Uganda. |
| spellingShingle | Chang, Y Ziegler, J Wabinga, H Katangole-Mbidde, E Boshoff, C Schulz, T Whitby, D Maddalena, D Jaffe, H Weiss, R Moore, P Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. |
| title | Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. |
| title_full | Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. |
| title_fullStr | Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. |
| title_full_unstemmed | Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. |
| title_short | Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. |
| title_sort | kaposi s sarcoma associated herpesvirus and kaposi s sarcoma in africa uganda kaposi s sarcoma study group |
| work_keys_str_mv | AT changy kaposissarcomaassociatedherpesvirusandkaposissarcomainafricaugandakaposissarcomastudygroup AT zieglerj kaposissarcomaassociatedherpesvirusandkaposissarcomainafricaugandakaposissarcomastudygroup AT wabingah kaposissarcomaassociatedherpesvirusandkaposissarcomainafricaugandakaposissarcomastudygroup AT katangolembiddee kaposissarcomaassociatedherpesvirusandkaposissarcomainafricaugandakaposissarcomastudygroup AT boshoffc kaposissarcomaassociatedherpesvirusandkaposissarcomainafricaugandakaposissarcomastudygroup AT schulzt kaposissarcomaassociatedherpesvirusandkaposissarcomainafricaugandakaposissarcomastudygroup AT whitbyd kaposissarcomaassociatedherpesvirusandkaposissarcomainafricaugandakaposissarcomastudygroup AT maddalenad kaposissarcomaassociatedherpesvirusandkaposissarcomainafricaugandakaposissarcomastudygroup AT jaffeh kaposissarcomaassociatedherpesvirusandkaposissarcomainafricaugandakaposissarcomastudygroup AT weissr kaposissarcomaassociatedherpesvirusandkaposissarcomainafricaugandakaposissarcomastudygroup AT moorep kaposissarcomaassociatedherpesvirusandkaposissarcomainafricaugandakaposissarcomastudygroup |